Worldwide experience of homozygous familial hypercholesterolaemia: retrospective cohort study

G. Francis | R. Hegele | M. Reijman | G. Kolovou | K. Lalić | F. Raal | R. Santos | D. Blom | M. Charng | D. Cassiman | M. Bourbon | E. Bruckert | M. Arca | O. Descamps | S. Azar | Ž. Reiner | P. Calabrò | P. Witters | M. Bucci | T. Sampietro | A. Catapano | U. Groselj | M. Harada‐Shiba | R. Češka | L. Kaynar | M. Elisaf | S. Bertolini | H. Soran | L. Hudgins | J. Genest | A. Fahed | M. Kayıkçıoğlu | P. Horák | R. Durst | E. Leitersdorf | R. Mehta | S. Greber-Platzer | K. Ray | Brooke A. Kennedy | L. Brunham | H. Cohen | G. Iannuzzo | S. Sag | G. Nemer | P. Tarugi | S. Calandra | L. Pisciotta | G. Hovingh | C. Rabacchi | C. Gokce | J. Dvořáková | I. Ruel | E. Kurtoğlu | O. Ozcebe | M. Averna | O. Ilhan | L. Tichý | Long Jiang | Luya Wang | V. Bláha | V. Soška | T. Freiberger | S. Demircioğlu | A. Temizhan | A. Cicero | A. Elis | M. Ezhov | M. Zenti | S. Béliard | J. Pang | W. Khovidhunkit | H. Y. Yasar | L. D’Erasmo | T. Fasano | J. Defesche | P. S. Buonuomo | A. Bartuli | E. Dann | P. Suppressa | E. Negri | A. Giammanco | M. Aktan | A. Gallo | J. Brothers | M. Hori | M. Casula | I. Verma | M. Kose | Z. Pekkolay | E. Stroes | A. Reda | M. Vrablik | F. Sbrana | M. Cuchel | C. Pavanello | F. Bitar | A. Cupido | A. Vallejo-Vaz | C. Stevens | Mutaz Al-khnifsawi | K. Chlebus | O. Mitchenko | A. Susekov | T. Truong | C. Nguyen | C. Ebenbichler | E. Moubarak | D. Rymen | Khalid Al-Waili | A. Wiegman | L. Zlatohlávek | H. Vaverkova | J. E. R. Lennep | M. Sherman | M. Ayesh | O. Hussein | S. Bertolini | C. Ripoli | A. Shek | R. Alieva | H. Nawawi | Khalid Bin Thani | A. Pasta | M. Hartgers | B. Altunkeser | T. Tromp | Mohammed Alareedh | S. D’Addato | C. Trenti | A. Costanzo | G. Watts | M. Yenerçağ | I. Gaspar | A. Ibba | Foaad Shaghee | I. Kuku | T. Le | Sameh Emil | T. Stulnig | A. Lyons | M. Gazzotti | H. Okutan | D. Schurr | Martin Mäser | R. Urbánek | S. Zemek | D. Do | M. Nguyen | N. Kim | H. Le | N. Setia | A. B. Cefalù | Lubomir Dlouhy | Tarek Naguib | A. F. A. Al-Zamili | S. H. Rhadi | F. Sileo | R. Madriz | L. Zuurbier | Fouzia Sadiq | O. Salcioglu | M. Yilmaz | S. Bertolini | F. Sadiq | T. Naguib | Merel L Hartgers | G Kees Hovingh | Antonio J Vallejo-Vaz | Stefano Bertolini | Dirk J Blom | Frederick J Raal | Merel L. Hartgers | G. Kees Hovingh | Antonio J. Vallejo-Vaz | Stefano A. Bertolini | A. D. Costanzo | Dirk J. Blom | Frederick J. Raal | Sinan Demircioğlu | Mustafa Yenerçağ | H. Yasar | M. Vrablík | J. R. Lennep | P. Buonuomo | Linda Zuurbier | K. Al-Waili | S. Emil | M. Mäser | M. Al-Khnifsawi | A. F. Al-Zamili | Foaad K. Shaghee | A. Cefalù

[1]  Andrew B. Kirke,et al.  Integrated Guidance for Enhancing the Care of Familial Hypercholesterolaemia in Australia. , 2020, Heart, lung & circulation.

[2]  M. Arca,et al.  Homozygous familial hypercholesterolemia in Italy: Clinical and molecular features. , 2020, Atherosclerosis.

[3]  D. Gaudet,et al.  Evinacumab for Homozygous Familial Hypercholesterolemia. , 2020, The New England journal of medicine.

[4]  C. Aguilar-Salinas,et al.  Phenotypical, Clinical, and Molecular Aspects of Adults and Children With Homozygous Familial Hypercholesterolemia in Iberoamerica , 2020, Arteriosclerosis, thrombosis, and vascular biology.

[5]  G. Watts,et al.  Prevalence of Familial Hypercholesterolemia Among the General Population and Patients With Atherosclerotic Cardiovascular Disease , 2020, Circulation.

[6]  B. Nordestgaard,et al.  Worldwide Prevalence of Familial Hypercholesterolemia: Meta-Analyses of 11 Million Subjects. , 2020, Journal of the American College of Cardiology.

[7]  G. Kolovou,et al.  Practice of lipoprotein apheresis and short-term efficacy in children with homozygous familial hypercholesterolemia: Data from an international registry. , 2020, Atherosclerosis.

[8]  G. Watts,et al.  Long-Term Evolocumab in Patients With Familial Hypercholesterolemia. , 2020, Journal of the American College of Cardiology.

[9]  M. D. Di Minno,et al.  A Real-World Experience of Clinical, Biochemical and Genetic Assessment of Patients with Homozygous Familial Hypercholesterolemia , 2020, Journal of clinical medicine.

[10]  F. Kronenberg,et al.  Rare dyslipidaemias, from phenotype to genotype to management: a European Atherosclerosis Society task force consensus statement. , 2020, The lancet. Diabetes & endocrinology.

[11]  M. Sabatine,et al.  2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. , 2019, European heart journal.

[12]  G. Watts,et al.  A cross-national investigation of cardiovascular survival in homozygous familial hypercholesterolemia: The Sino-Roman Study. , 2019, Journal of clinical lipidology.

[13]  G. Kolovou,et al.  Real-World Outcomes with Lomitapide Use in Paediatric Patients with Homozygous Familial Hypercholesterolaemia , 2019, Advances in Therapy.

[14]  L. Tokgozoglu,et al.  Clinical management, psychosocial characteristics, and quality of life in patients with homozygous familial hypercholesterolemia undergoing LDL-apheresis in Turkey: Results of a nationwide survey (A-HIT1 registry). , 2019, Journal of clinical lipidology.

[15]  J. Car,et al.  Overview of the current status of familial hypercholesterolaemia care in over 60 countries - The EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC). , 2018, Atherosclerosis.

[16]  E. Bruckert,et al.  Lipoprotein-apheresis in familial hypercholesterolemia: Long-term patient compliance in a French cohort. , 2018, Atherosclerosis.

[17]  D. Ledbetter,et al.  Clinical Genetic Testing for Familial Hypercholesterolemia: JACC Scientific Expert Panel. , 2018, Journal of the American College of Cardiology.

[18]  F. Raal,et al.  Survival in homozygous familial hypercholesterolaemia is determined by the on-treatment level of serum cholesterol , 2018, European heart journal.

[19]  C. Sirtori,et al.  Autosomal Recessive Hypercholesterolemia: Long-Term Cardiovascular Outcomes. , 2018, Journal of the American College of Cardiology.

[20]  G. Watts,et al.  Toward an international consensus-Integrating lipoprotein apheresis and new lipid-lowering drugs. , 2017, Journal of clinical lipidology.

[21]  Lale Tokgözoğlu,et al.  Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel , 2017, European heart journal.

[22]  G. Watts,et al.  Long-term treatment with evolocumab added to conventional drug therapy, with or without apheresis, in patients with homozygous familial hypercholesterolaemia: an interim subset analysis of the open-label TAUSSIG study. , 2017, The lancet. Diabetes & endocrinology.

[23]  K. Widhalm,et al.  Homozygous familial hypercholesterolemia: Summarized case reports. , 2017, Atherosclerosis.

[24]  C. Shoulders,et al.  HEART UK statement on the management of homozygous familial hypercholesterolaemia in the United Kingdom. , 2016, Atherosclerosis.

[25]  L. Pérez de Isla,et al.  Clinical and molecular characteristics of homozygous familial hypercholesterolemia patients: Insights from SAFEHEART registry. , 2016, Journal of clinical lipidology.

[26]  Gerald F. Watts,et al.  Homozigot ailevi hiperkolesterolemi: klinisyenlerin taniyi ve klinik yönetimi gelistirmelerine yönelik yeni anlayislar ve rehberlik. Avrupa Ateroskleroz Dernegi'nin Ailevi Hiperkolesterolemi Üzerine Uzlasi Paneli yazili görüsü. , 2015 .

[27]  E. Sijbrands,et al.  Homozygous autosomal dominant hypercholesterolaemia in the Netherlands: prevalence, genotype-phenotype relationship, and clinical outcome. , 2015, European heart journal.

[28]  D. Gaudet,et al.  Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study , 2013, The Lancet.

[29]  J. Danesh,et al.  Major lipids, apolipoproteins, and risk of vascular disease. , 2009, JAMA.